Coates LC, Soriano ER, Corp N, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18:465–79.

PubMed  PubMed Central  Google Scholar 

Haugeberg G, Michelsen B, Kavanaugh A. Impact of skin, musculoskeletal and psychosocial aspects on quality of life in psoriatic arthritis patients: A cross-sectional study of outpatient clinic patients in the biologic treatment era. RMD Open. 2020;6:e001223.

PubMed  PubMed Central  Google Scholar 

Husted JA, Thavaneswaran A, Chandran V, et al. Incremental effects of comorbidity on quality of life in patients with psoriatic arthritis. J Rheumatol. 2013;40:1349–56.

PubMed  Google Scholar 

Kerschbaumer A, Baker D, Smolen JS, et al. The effects of structural damage on functional disability in psoriatic arthritis. Ann Rheum Dis. 2017;76:2038–45.

CAS  PubMed  Google Scholar 

Zhao SS, Miller N, Harrison N, et al. Systematic review of mental health comorbidities in psoriatic arthritis. Clin Rheumatol. 2020;39:217–25.

PubMed  Google Scholar 

Michelsen B, Kristianslund EK, Sexton J, et al. Do depression and anxiety reduce the likelihood of remission in rheumatoid arthritis and psoriatic arthritis? Data from the prospective multicentre NOR-DMARD study. Ann Rheum Dis. 2017;76:1906–10.

PubMed  Google Scholar 

Lubrano E, Scriffignano S, Perrotta FM. Clinical characteristics of “severe” peripheral psoriatic arthritis: a retrospective analysis of a longitudinal cohort. Rheumatol Ther. 2024;11:663–74.

PubMed  PubMed Central  Google Scholar 

Queiro R, Seoane-Mato D, Laiz A, et al. Severe disease in patients with recent-onset psoriatic arthritis. Prediction model based on machine learning. Front Med (Lausanne). 2022;9:891863.

PubMed  Google Scholar 

Ogdie A, Coates LC, Mease P. Measuring outcomes in psoriatic arthritis. Arthritis Care Res (Hoboken). 2020;72:82–109.

PubMed  PubMed Central  Google Scholar 

Eder L, Thavaneswaran A, Chandran V, et al. Factors explaining the discrepancy between physician and patient global assessment of joint and skin disease activity in psoriatic arthritis patients. Arthritis Care Res (Hoboken). 2015;67:264–72.

PubMed  Google Scholar 

Lebwohl MG, Kavanaugh A, Armstrong AW, et al. US perspectives in the management of psoriasis and psoriatic arthritis: patient and physician results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey. Am J Clin Dermatol. 2016;17:87–97.

PubMed  Google Scholar 

Sacristán JA, Dilla T, Díaz-Cerezo S, et al. Patient-physician discrepancy in the perception of immune-mediated inflammatory diseases: rheumatoid arthritis, psoriatic arthritis and psoriasis. A qualitative systematic review of the literature. PLoS One. 2020;15:e0234705.

PubMed  PubMed Central  Google Scholar 

Mease PJ, Karki C, Palmer JB, et al. Clinical and patient-reported outcomes in patients with psoriatic arthritis (PsA) by body surface area affected by psoriasis: results from the Corrona PsA/Spondyloarthritis Registry. J Rheumatol. 2017;44:1151–8.

PubMed  Google Scholar 

Mease PJ, Karki C, Palmer JB, et al. Clinical characteristics, disease activity, and patient-reported outcomes in psoriatic arthritis patients with dactylitis or enthesitis: results from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. Arthritis Care Res (Hoboken). 2017;69:1692–9.

CAS  PubMed  Google Scholar 

Mease PJ, Liu M, Rebello S, et al. Association of nail psoriasis with disease activity measures and impact in psoriatic arthritis: data from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. J Rheumatol. 2021;48:520–6.

PubMed  Google Scholar 

Mease PJ, Palmer JB, Liu M, et al. Influence of axial involvement on clinical characteristics of psoriatic arthritis: analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. J Rheumatol. 2018;45:1389–96.

PubMed  Google Scholar 

Tillett W, Merola JF, Thaci D, et al. Disease characteristics and the burden of joint and skin involvement amongst people with psoriatic arthritis: a population survey. Rheumatol Ther. 2020;7:617–37.

PubMed  PubMed Central  Google Scholar 

McInnes IB, Rahman P, Gottlieb AB, et al. Efficacy and safety of guselkumab, an interleukin-23p19-specific monoclonal antibody, through one year in biologic-naive patients with psoriatic arthritis. Arthritis Rheumatol. 2021;73:604–16.

CAS  PubMed  PubMed Central  Google Scholar 

Ritchlin CT, Helliwell PS, Boehncke WH, et al. Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced. RMD Open. 2021;7:e001457.

PubMed  PubMed Central  Google Scholar 

McInnes IB, Rahman P, Gottlieb AB, et al. Long-term efficacy and safety of guselkumab, a monoclonal antibody specific to the p19 subunit of interleukin-23, through two years: Results from a phase III, randomized, double-blind, placebo-controlled study conducted in biologic-naive patients with active psoriatic arthritis. Arthritis Rheumatol. 2022;74:475–85.

CAS  PubMed  PubMed Central  Google Scholar 

Coates LC, Gossec L, Zimmerman M, et al. Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo controlled study. RMD Open. 2024;10:e003977.

PubMed  PubMed Central  Google Scholar 

Ritchlin CT, Mease PJ, Boehncke WH, et al. Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 study. Clin Rheumatol. 2024;43:2551–63.

PubMed  PubMed Central  Google Scholar 

Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naïve patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395:1126–36.

CAS  PubMed  Google Scholar 

Schoels M, Aletaha D, Funovits J, et al. Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis. Ann Rheum Dis. 2010;69:1441–7.

PubMed  Google Scholar 

Chandran V, Bhella S, Schentag C, et al. Functional assessment of chronic illness therapy-fatigue scale is valid in patients with psoriatic arthritis. Ann Rheum Dis. 2007;66:936–9.

PubMed  PubMed Central  Google Scholar 

Schoels MM, Aletaha D, Alasti F, et al. Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis. 2016;75:811–8.

PubMed  Google Scholar 

Helliwell PS, FitzGerald O, Fransen J, et al. The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis. 2013;72:986–91.

PubMed  Google Scholar 

Helliwell PS, Deodhar A, Gottlieb AB, et al. Composite measures of disease activity in psoriatic arthritis: comparative instrument performance based on the efficacy of guselkumab in an interventional phase II trial. Arthritis Care Res (Hoboken). 2020;72:1579–88.

CAS  PubMed  PubMed Central  Google Scholar 

Cauli A, Gladman DD, Mathieu A, et al. Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study. J Rheumatol. 2011;38:898–903.

PubMed  Google Scholar 

Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis. 2010;69:48–53.

CAS  PubMed  Google Scholar 

Lubrano E, Perrotta FM, Parsons WJ, et al. Patient’s global assessment as an outcome measure for psoriatic arthritis in clinical practice: a surrogate for measuring low disease activity? J Rheumatol. 2015;42:2332–8.

CAS  PubMed  Google Scholar 

Haroon M, Gallagher P, FitzGerald O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann Rheum Dis. 2015;74:1045–50.

CAS  PubMed  Google Scholar 

Snoeck Henkemans SVJ, de Jong PHP, Luime JJ, et al. Window of opportunity in psoriatic arthritis: the earlier the better? RMD Open. 2024;10:e004062.

PubMed  PubMed Central  Google Scholar 

Gottlieb AB, McInnes IB, Rahman P, et al. Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naive patients with active psoriatic arthritis. RMD Open. 2023;9:e002789.

PubMed  PubMed Central  Google Scholar 

Talli S, Etcheto A, Fautrel B, et al. Patient global assessment in psoriatic arthritis—What does it mean? An analysis of 223 patients from the psoriatic arthritis impact of disease (PsAID) study. Joint Bone Spine. 2016;83:335–40.

PubMed  Google Scholar 

Lubrano E, Scriffignano S, Azuaga AB, et al. Impact of comorbidities on disease activity, patient global assessment, and function in psoriatic arthritis: a cross-sectional study. Rheumatol Ther. 2020;7:825–36.

PubMed  PubMed Central  Google Scholar 

Mease PJ, Gladman DD, Poddubnyy D, et al. Efficacy of guselkumab on axial-related symptoms through up to 2 years in adults with active psoriatic arthritis in the phase 3, randomized, placebo-controlled DISCOVER-2 study. Rheumatol Ther. 2023;10:1637–53.

PubMed  PubMed Central  Google Scholar 

Mease PJ, Helliwell PS, Gladman DD, et al. Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies. Lancet Rheumatol. 2021;3:e715–23.

CAS  PubMed